Published in Oncol Lett on July 20, 2017
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Cancer immunotherapy comes of age. Nature (2011) 12.35
Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 6.26
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology (2004) 2.90
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology (2002) 2.85
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol (2015) 2.68
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol (2015) 2.52
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet (1999) 2.27
Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol (2005) 2.21
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity (2016) 1.96
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol (2012) 1.72
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst (2007) 1.70
Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol (2010) 1.62
Markers for individualised therapy in endometrial carcinoma. Lancet Oncol (2012) 1.61
Classification of endometrial carcinoma: more than two types. Lancet Oncol (2014) 1.53
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev (2015) 1.53
Molecular pathology of endometrial carcinoma. Histopathology (2013) 1.28
An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One (2010) 1.26
Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers (2004) 1.22
Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res (2002) 1.20
Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol (2002) 1.19
Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res (2016) 1.18
Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis (2006) 1.05
DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol (2009) 1.03
Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol (2009) 1.01
Classification and characterization of microsatellite instability across 18 cancer types. Nat Med (2016) 0.97
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
The emerging genomic landscape of endometrial cancer. Clin Chem (2013) 0.94
Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer (2010) 0.92
Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol (2012) 0.91
Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol (2014) 0.89
Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours. Br J Cancer (2013) 0.78
Intravenous low-grade endometrial stromal sarcoma with intracardiac extension: A CASE OF inaccurate tumor location on contrast-enhanced computed tomography. Mol Clin Oncol (2015) 0.79
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. Oncol Lett (2017) 0.75
Recent advances in the molecular mechanisms of Mayer-Rokitansky-Küster-Hauser syndrome. Biomed Rep (2017) 0.75
Aberrant chromatin remodeling in gynecological cancer. Oncol Lett (2017) 0.75
Recent findings on epigenetic gene abnormalities involved in uterine cancer. Mol Clin Oncol (2017) 0.75
Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer (2017) 0.75